Dominique Cheneval, Ph.D., Founder and Chief Operating Officer
Dr. Cheneval has close to thirty years experience in the pharmaceutical
industry. He has held positions with the pharmaceutical giants Sandoz and
Novartis, where he led teams in cutting edge research both in numerous drug
discovery programs and compound profiling.
In addition to his research and pre-clinical development activities, he has received training in pharmaceutical development, leadership and business management.
Dr. Cheneval graduated with a Ph.D. in Biochemistry from the Swiss Federal Institute of Technology (ETH, Zürich) and was a Postdoctoral Research Fellow at The Johns Hopkins University School of Medicine (Baltimore, Maryland).
Tania Kastelic, Ph.D., Founder and Vice President Scientific Affairs
Dr. Kastelic has more than twenty-five years of pharmaceutical industry experience including positions as Postdoctoral Fellow and Research Associate with Sandoz and Novartis Pharma AG (Switzerland). She was involved in several drug discovery projects in the field of inflammation and rheumatoid arthritis.
Dr. Kastelic is the discoverer of Novation's novel and unique mRNA modulation technology. She brings to Novation superior research skills, proven by her recognition of the potential of modulating mRNA stability as a therapeutic target for orally active drugs.
Dr. Kastelic has a Ph.D. from the Biochemistry, Cellular and Molecular Biology Program of The Johns Hopkins University School of Medicine (Baltimore, Maryland) and a Master of Science in Chemistry from Simon Fraser University (Burnaby, B.C.).